Credit Suisse Starts Fulgent Genetics (FLGT) at Outperform

October 24, 2016 6:30 AM EDT
Get Alerts FLGT Hot Sheet
Price: $13.67 --0%

Rating Summary:
    3 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 0 | Down: 0 | New: 0
Trade FLGT Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

Credit Suisse initiates coverage on Fulgent Genetics (NASDAQ: FLGT) with a Outperform rating and a price target of $13.00.

Analyst Erin Wilson commented, "FLGT is a rapidly-growing genetic testing company, leveraging a proprietary technology platform to provide physicians with relevant diagnostic information. Its analytics platform supports the broadest test menu (18,000+ genes) in the industry, and it performs tests at a low internal cost, a meaningful competitive advantage. It should gain share in a nascent genetic testing market while maintaining an attractive profit profile ahead of other genetic testing companies."

For an analyst ratings summary and ratings history on Fulgent Genetics click here. For more ratings news on Fulgent Genetics click here.

Shares of Fulgent Genetics closed at $8.88 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, New Coverage

Related Entities

Credit Suisse, Erin Wilson

Add Your Comment